経カテーテル心臓弁置換術の世界市場：洞察、競合情勢、市場予測：2030年

経カテーテル心臓弁置換術の市場規模は、2024年から2030年までの予測期間中に13.75%のCAGRで拡大すると予測されています。経カテーテル心臓弁置換術市場は、循環器疾患、様々な心臓弁疾患を含む心血管疾患の有病率の上昇、規制クリアランスなどの製品開発活動の増加、座りがちなライフスタイル、生活習慣病の増加、2024年から2030年までの予測期間中に経カテーテル心臓弁置換術市場の全体的な成長をエスカレートさせると予想される低侵襲手術への嗜好の増加により急速に拡大しています。

英国心臓財団（BHF）によると、2024年には、ライフスタイルの変化、高齢化、人口増加により、2022年には世界中で約6億4,000万人が心臓・循環器疾患を抱えて生活していると報告されています。

世界保健機関（WHO）の2020年のデータによると、石灰沈着性大動脈弁狭窄症の有病率は世界中で900万人でした。このように、循環器疾患や様々な心臓弁疾患を含む心血管疾患の有病率の上昇は、経カテーテル心臓弁置換術の需要を増加させるとみられています。

また、低侵襲手術に対する患者の嗜好の高まりも、予測期間中の市場成長に好材料となりそうです。経カテーテル心臓弁置換術は、その低侵襲的なアプローチにより、従来の手術に比べて、回復時間の短縮、術後の痛みの軽減、入院期間の短縮、創合併症の軽減、より優れた創プロテーゼなどの利点を提供します。

当レポートでは、世界の経カテーテル心臓弁置換術市場について調査し、市場の概要とともに、製品別、用途別、エンドユーザー別動向、競合情勢、国別動向などを提供しています。

目次

第1章 経カテーテル心臓弁置換術市場レポートのイントロダクション

第2章 経カテーテル心臓弁置換術市場のエグゼクティブサマリー

第3章 競合情勢

第4章 規制分析

• 米国
• 欧州
• 日本
• 中国

第5章 経カテーテル心臓弁置換術市場の主な要因分析

• 経カテーテル心臓弁置換術市場の促進要因
• 経カテーテル心臓弁置換術市場の抑制要因と課題
• 経カテーテル心臓弁置換術市場の機会

第6章 経カテーテル心臓弁置換術市場のポーターのファイブフォース分析

第7章 経カテーテル心臓弁置換術の市場評価

• 製品別
• 用途別
• エンドユーザー別
• 地域別

第8章 経カテーテル心臓弁置換術市場の企業と製品プロファイル

• Medtronic
• Boston Scientific Corporation
• Bracco SpA
• Edward Lifesciences
• Meril Lifesciences
• JenaValve Technologies Inc.
• Venus Medtech (Hangzhou) Inc.
• Abbott
• Bluesail Medical Co., Ltd.
• Braile Biomedica
• CryoLife, Inc.
• SMT
• Peijia Medical Limited
• P+F Products + Features GmbH
• Livanova Plc

第9章 KOLの見解

第10章 プロジェクトのアプローチ

第11章 DelveInsightについて

第12章 免責事項とお問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: Transcatheter Heart Valve Replacement Market in Global (2021-2030)
• Table 3: Transcatheter Heart Valve Replacement Market in Global by Product (2021-2030)
• Table 4: Transcatheter Heart Valve Replacement Market in Global by Application (2021-2030)
• Table 5: Transcatheter Heart Valve Replacement Market in Global by End-User (2021-2030)
• Table 6: Transcatheter Heart Valve Replacement Market in Global by Geography (2021-2030)
• Table 7: Transcatheter Heart Valve Replacement Market in North America (2021-2030)
• Table 8: Transcatheter Heart Valve Replacement Market in the United States (2021-2030)
• Table 9: Transcatheter Heart Valve Replacement Market in Canada (2021-2030)
• Table 10: Transcatheter Heart Valve Replacement Market in Mexico (2021-2030)
• Table 11: Transcatheter Heart Valve Replacement Market in Europe (2021-2030)
• Table 12: Transcatheter Heart Valve Replacement Market in France (2021-2030)
• Table 13: Transcatheter Heart Valve Replacement Market in Germany (2021-2030)
• Table 14: Transcatheter Heart Valve Replacement Market in United Kingdom (2021-2030)
• Table 15: Transcatheter Heart Valve Replacement Market in Italy (2021-2030)
• Table 16: Transcatheter Heart Valve Replacement Market in Spain (2021-2030)
• Table 17: Transcatheter Heart Valve Replacement Market in the Rest of Europe (2021-2030)
• Table 18: Transcatheter Heart Valve Replacement Market in Asia-Pacific (2021-2030)
• Table 19: Transcatheter Heart Valve Replacement Market in China (2021-2030)
• Table 20: Transcatheter Heart Valve Replacement Market in Japan (2021-2030)
• Table 21: Transcatheter Heart Valve Replacement Market in India (2021-2030)
• Table 22: Transcatheter Heart Valve Replacement Market in Australia (2021-2030)
• Table 23: Transcatheter Heart Valve Replacement Market in South Korea (2021-2030)
• Table 24: Transcatheter Heart Valve Replacement Market in Rest of Asia-Pacific (2021-2030)
• Table 25: Transcatheter Heart Valve Replacement Market in the Rest of the World (2021-2030)
• Table 26: Transcatheter Heart Valve Replacement Market in the Middle East (2021-2030)
• Table 27: Transcatheter Heart Valve Replacement Market in Africa (2021-2030)
• Table 28: Transcatheter Heart Valve Replacement Market in South America (2021-2030)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: Transcatheter Heart Valve Replacement Market in Global (2021-2030)
• Figure 3: Transcatheter Heart Valve Replacement Market in Global by Product (2021-2030)
• Figure 4: Transcatheter Heart Valve Replacement Market in Global by Application (2021-2030)
• Figure 5: Transcatheter Heart Valve Replacement Market in Global by End-User (2021-2030)
• Figure 6: Transcatheter Heart Valve Replacement Market in Global by Geography (2021-2030)
• Figure 7: Transcatheter Heart Valve Replacement Market in North America (2021-2030)
• Figure 8: Transcatheter Heart Valve Replacement Market in the United States (2021-2030)
• Figure 9: Transcatheter Heart Valve Replacement Market in Canada (2021-2030)
• Figure 10: Transcatheter Heart Valve Replacement Market in Mexico (2021-2030)
• Figure 11: Transcatheter Heart Valve Replacement Market in Europe (2021-2030)
• Figure 12: Transcatheter Heart Valve Replacement Market in France (2021-2030)
• Figure 13: Transcatheter Heart Valve Replacement Market in Germany (2021-2030)
• Figure 14: Transcatheter Heart Valve Replacement Market in United Kingdom (2021-2030)
• Figure 15: Transcatheter Heart Valve Replacement Market in Italy (2021-2030)
• Figure 16: Transcatheter Heart Valve Replacement Market in Spain (2021-2030)
• Figure 17: Transcatheter Heart Valve Replacement Market in the Rest of Europe (2021-2030)
• Figure 18: Transcatheter Heart Valve Replacement Market in Asia-Pacific (2021-2030)
• Figure 19: Transcatheter Heart Valve Replacement Market in China (2021-2030)
• Figure 20: Transcatheter Heart Valve Replacement Market in Japan (2021-2030)
• Figure 21: Transcatheter Heart Valve Replacement Market in India (2021-2030)
• Figure 22: Transcatheter Heart Valve Replacement Market in Australia (2021-2030)
• Figure 23: Transcatheter Heart Valve Replacement Market in South Korea (2021-2030)
• Figure 24: Transcatheter Heart Valve Replacement Market in Rest of Asia-Pacific (2021-2030)
• Figure 25: Transcatheter Heart Valve Replacement Market in the Rest of the World (2021-2030)
• Figure 26: Transcatheter Heart Valve Replacement Market in the Middle East (2021-2030)
• Figure 27: Transcatheter Heart Valve Replacement Market in Africa (2021-2030)
• Figure 28: Transcatheter Heart Valve Replacement Market in South America (2021-2030)
• Figure 29: Market Drivers
• Figure 30: Market Barriers
• Figure 31: Marker Opportunities
• Figure 32: PORTER'S Five Force Analysis

Transcatheter Heart Valve Replacement Market by Product (Transcatheter Aortic Valve Replacement, Transcatheter Mitral Valve Replacement, and Transcatheter Pulmonary Valve Replacement), Application (Aortic Valve Stenosis, Aortic Valve Regurgitation, Mitral Valve Stenosis, Mitral Valve Regurgitation, and Others), End-User (Hospitals, Specialty Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a respectable CAGR forecast till 2030 owing to the growing prevalence of cardiovascular disorders and increasing product developmental activities worldwide

The transcatheter heart valve replacement market is estimated to grow at a CAGR of 13.75% during the forecast period from 2024 to 2030. The transcatheter heart valve replacement market is expanding rapidly due to the growing prevalence of cardiovascular disorders including circulatory diseases, various heart valve diseases, increasing product developmental activities such as regulatory clearances, rising sedentary lifestyle & lifestyle-associated disorders, increasing preference for minimally invasive surgeries that are expected to escalate the overall growth of the transcatheter heart valve replacement market during the forecast period from 2024 to 2030.

Transcatheter Heart Valve Replacement Market Dynamics:

According to the British Heart Foundation (BHF), it was reported in 2024, that around 640 million people in 2022 were living with heart and circulatory diseases across the world owing to changing lifestyles, aging, and a growing population.

As per data from the World Health Organization (WHO) 2020, the prevalence of calcific aortic valve stenosis was 9 million across the world. Thus, the increasing prevalence of cardiovascular diseases including circulatory diseases and various heart valve diseases will increase the demand for transcatheter heart valve replacement.

The increasing patient preference for minimally invasive surgeries is also likely to bode well for the market growth during the forecast period. Transcatheter heart valve replacement offer advantages over conventional surgeries owing to their minimally invasive approach, such as shorter recovery time, less post-operational pain, less stay at the hospital, fewer wound complications, and better wound prosthesis.

Additionally, in February 2024, Edwards Lifesciences Corporation announced launch of the Sapien 3 Ultra Resilia valve in Europe.

Therefore, the factors stated above collectively will drive the overall transcatheter heart valve replacement market growth.

However, presence of alternative treatment in the market, stringent regulatory approval process, among others may prove to be challenging factors for transcatheter heart valve replacement market growth.

Transcatheter Heart Valve Replacement Market Segment Analysis:

Transcatheter Heart Valve Replacement Market by Product (Transcatheter Aortic Valve Replacement, Transcatheter Mitral Valve Replacement, and Transcatheter Pulmonary Valve Replacement), Application (Aortic Valve Stenosis, Aortic Valve Regurgitation, Mitral Valve Stenosis, Mitral Valve Regurgitation, and Others), End-User (Hospitals, Specialty Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product segment of the transcatheter heart valve replacement market, the transcatheter aortic valve replacement (TAVR) category is expected to have a significant revenue share in the year 2023. This is due to the increasing cases of aortic stenosis disorder as TAVR is the first-line surgical procedure performed for aortic stenosis. Further, the availability of technologically advanced devices in the market, and rising device launches and approvals will also affect the market positively.

The primary feature of this technique is its minimally invasive nature, as it involves accessing the aorta through the femoral artery in the groin, which typically results in a smaller incision and less surgical trauma. This approach leads to significant benefits, including a shorter recovery time.

Additionally, advancements in imaging and device technology have improved the precision of valve placement during the procedure, leading to better overall results. The transfemoral approach is also beneficial for patients with favorable femoral artery anatomy, as it allows for straightforward access without the need for complex surgical interventions.

Therefore the widespread uses and various features of transcatheter aortic valve replacement enhance performance and usability, solidifying the significant impact on the growth of the overall transcatheter heart valve replacement market during the forecast period from 2024 to 2030.

North America is expected to dominate the overall transcatheter heart valve replacement market:

Among all the regions, North America is expected to dominate the transcatheter heart valve replacement market in the year 2023 and is expected to do the same during the forecast period. This can be attributed to several factors including the high instances of myocardial infarction, heart valve diseases, and their associated risk factors, combined with significant advancements in product development & regulatory approvals, the presence of market key players, and the availability of well-established advanced healthcare infrastructure that are acting as key factors contributing to the growth of the transcatheter heart valve replacement market in the North America region during the forecast period from 2024 to 2030.

Disease Control and Prevention (CDC) (2024), it was stated that 805,000 people in the US have a myocardial infarction (heart attack) every year on average. Furthermore, as per the same source, it was stated that heart disease is an umbrella term that encompasses numerous indications. Some of the key risk factors associated with heart disease are high blood cholesterol, high blood pressure, and smoking. The source further mentioned that about half of Americans (47%) have at least one of these three risk factors.

According to the Canadian Cardiovascular Society (2022), it was reported that in 2022, 2.5% of the population had heart valve diseases, which is increasing significantly after the age of 65, reaching up to 13% after the age of 75. It was also estimated by the same source that in 2040, Canada will have an estimated 1.5 million people over 65 years with heart valve disease.

Since cardiovascular disorders are rising in the region among middle-aged individuals, the demand for more effective treatment options is increasing significantly. This trend is fueling investment in innovative technologies and expanding the market for transcatheter heart valve replacement.

Rising product developmental activities by regulatory bodies and key players in the region will further boost the market for transcatheter heart valve replacement. For example, in September 2021, Abbott announced that the U.S Food and Drug Administration approved the company's Portico(TM) with FlexNav(TM) transcatheter aortic valve replacement (TAVR) system to treat people with symptomatic, severe aortic stenosis who are at high or extreme risk for open-heart surgery.

Therefore, the interplay of all the aforementioned factors would provide a conducive growth environment for the North American transcatheter heart valve replacement market.

Transcatheter Heart Valve Replacement Market key players:

Some of the key market players operating in the transcatheter heart valve replacement market include Medtronic, Boston Scientific Corporation, Bracco SpA, Edward Lifesciences, Meril Lifesciences, JenaValve Technologies Inc., Venus Medtech (Hangzhou) Inc., Abbott, Bluesail Medical Co., Ltd., Braile Biomedica, CryoLife, Inc., SMT, Peijia Medical Limited, P+F Products + Features GmbH, Livanova Plc, and others.

Recent Developmental Activities in the Transcatheter Heart Valve Replacement Market:

• In August 2024, Boston Scientific Corporation announced that it secured CE mark for the ACURATE Prime(TM) Aortic Valve System, the newest transcatheter aortic valve replacement (TAVR) technology.
• In January 2022, Medtronic announced that the National Medical Products Administration (NMPA) approved the CoreValve Evolut PRO TAVR system for the treatment of severe aortic stenosis (AS) for symptomatic patients in China who are at high or extreme risk for open heart surgery.

Key Takeaways from the Transcatheter Heart Valve Replacement Market Report Study

• Market size analysis for current transcatheter heart valve replacement market size (2023), and market forecast for 6 years (2024 to 2030)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the transcatheter heart valve replacement market
• Various opportunities available for the other competitors in the Transcatheter Heart Valve Replacement market space
• What are the top-performing segments in 2023? How these segments will perform in 2030?
• Which are the top-performing regions and countries in the current transcatheter heart valve replacement market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for transcatheter heart valve replacement market growth in the coming future?

Target Audience who can be benefited from this Transcatheter Heart Valve Replacement Market Report Study

• Transcatheter heart valve replacement product providers
• Research organizations and consulting companies
• Transcatheter heart valve replacement-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in transcatheter heart valve replacement
• Various end-users who want to know more about the transcatheter heart valve replacement market and the latest technological developments in the transcatheter heart valve replacement market

Frequently Asked Questions for the Transcatheter Heart Valve Replacement Market:

1. What are transcatheter heart valve replacement?

• The transcatheter heart valve replacement is a procedure with a less invasive approach that helps replace the heart valve with a prosthetic valve to treat severe aortic stenosis and mitral regurgitation. It is an effective alternative to cumbersome open heart surgery, especially for high-risk patients.

2. What is the market for transcatheter heart valve replacement?

• The transcatheter heart valve replacement market is estimated to grow at a CAGR of 13.75% during the forecast period from 2024 to 2030.

3. What are the drivers for the transcatheter heart valve replacement market?

• The transcatheter heart valve replacement market is expanding rapidly due to the growing prevalence of cardiovascular disorders including circulatory diseases, various heart valve diseases, increasing product developmental activities such as regulatory clearances, rising sedentary lifestyle & lifestyle-associated disorders, increasing preference for minimally invasive surgeries that are expected to escalate the overall growth of the transcatheter heart valve replacement market during the forecast period from 2024 to 2030.

4. Who are the key players operating in the transcatheter heart valve replacement market?

• Some of the key market players operating in transcatheter heart valve replacement include Medtronic, Boston Scientific Corporation, Bracco SpA, Edward Lifesciences, Meril Lifesciences, JenaValve Technologies Inc., Venus Medtech (Hangzhou) Inc., Abbott, Bluesail Medical Co., Ltd., Braile Biomedica, CryoLife, Inc., SMT, Peijia Medical Limited, P+F Products + Features GmbH, Livanova Plc, and others.

5. Which region has the highest share in the transcatheter heart valve replacement market?

• Among all the regions, North America is expected to dominate the transcatheter heart valve replacement market in the year 2023 and is expected to do the same during the forecast period. This can be attributed to several factors including the high instances of myocardial infarction, heart valve diseases, and its associated risk factors, combined with significant advancements in product development & regulatory approvals, the presence of market key players, and the availability of well-established advanced healthcare infrastructure that are acting as key factors contributing to the growth of the transcatheter heart valve replacement market in the North America region during the forecast period from 2024 to 2030.

Table of Contents

1. Transcatheter Heart Valve Replacement Market Report Introduction

• 1.1. Scope of the Study
• 1.2. Market Segmentation
• 1.3. Market Assumption

2. Transcatheter Heart Valve Replacement Market Executive Summary

• 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

• 4.1. The United States
• 4.2. Europe
• 4.3. Japan
• 4.4. China

5. Transcatheter Heart Valve Replacement Market Key Factors Analysis

• 5.1. Transcatheter Heart Valve Replacement Market Drivers
  • 5.1.1. Growing prevalence of cardiovascular disorders
  • 5.1.2. Increasing product developmental activities
  • 5.1.3. Rising sedentary lifestyle and Increasing prevalence of lifestyle-associated disorders
• 5.2. Transcatheter Heart Valve Replacement Market Restraints and Challenges
  • 5.2.1. Presence of alternative treatment in the market
  • 5.2.2. Stringent regulatory approval process
• 5.3. Transcatheter Heart Valve Replacement Market Opportunities
  • 5.3.1. Presence of a robust number of replacement devices in the pipeline

6. Transcatheter Heart Valve Replacement Market Porter's Five Forces Analysis

• 6.1. Bargaining Power of Suppliers
• 6.2. Bargaining Power of Consumers
• 6.3. Threat of New Entrants
• 6.4. Threat of Substitutes
• 6.5. Competitive Rivalry

7. Transcatheter Heart Valve Replacement Market Assessment

• 7.1. By Product
  • 7.1.1. Transcatheter Aortic Valve Replacement
  • 7.1.2. Transcatheter Mitral Valve Replacement
  • 7.1.3. Transcatheter Pulmonary Valve Replacement
• 7.2. By Application
  • 7.2.1. Aortic Valve Stenosis
  • 7.2.2. Aortic Valve Regurgitation
  • 7.2.3. Mitral Valve Stenosis
  • 7.2.4. Mitral Valve Regurgitation
  • 7.2.5. Others
• 7.3. By End-User
  • 7.3.1. Hospitals
  • 7.3.2. Specialty Clinics
  • 7.3.3. Others
• 7.4. By Geography
  • 7.4.1. North America
    • 7.4.1.1. United States Transcatheter Heart Valve Replacement Market Size in USD million (2021-2030)
    • 7.4.1.2. Canada Transcatheter Heart Valve Replacement Market Size in USD million (2021-2030)
    • 7.4.1.3. Mexico Transcatheter Heart Valve Replacement Market Size in USD million (2021-2030)
  • 7.4.2. Europe
    • 7.4.2.1. France Transcatheter Heart Valve Replacement Market Size in USD million (2021-2030)
    • 7.4.2.2. Germany Transcatheter Heart Valve Replacement Market Size in USD million (2021-2030)
    • 7.4.2.3. United Kingdom Transcatheter Heart Valve Replacement Market Size in USD million (2021-2030)
    • 7.4.2.4. Italy Transcatheter Heart Valve Replacement Market Size in USD million (2021-2030)
    • 7.4.2.5. Spain Transcatheter Heart Valve Replacement Market Size in USD million (2021-2030)
    • 7.4.2.6. Rest of Europe Transcatheter Heart Valve Replacement Market Size in USD million (2021-2030)
  • 7.4.3. Asia-Pacific
    • 7.4.3.1. China Transcatheter Heart Valve Replacement Market Size in USD million (2021-2030)
    • 7.4.3.2. Japan Transcatheter Heart Valve Replacement Market Size in USD million (2021-2030)
    • 7.4.3.3. India Transcatheter Heart Valve Replacement Market Size in USD million (2021-2030)
    • 7.4.3.4. Australia Transcatheter Heart Valve Replacement Market Size in USD million (2021-2030)
    • 7.4.3.5. South Korea Transcatheter Heart Valve Replacement Market Size in USD million (2021-2030)
    • 7.4.3.6. Rest of Asia-Pacific Transcatheter Heart Valve Replacement Market Size in USD million (2021-2030)
  • 7.4.4. Rest of the World (RoW)
    • 7.4.4.1. Middle East Transcatheter Heart Valve Replacement Market Size in USD million (2021-2030)
    • 7.4.4.2. Africa Transcatheter Heart Valve Replacement Market Size in USD million (2021-2030)
    • 7.4.4.3. South America Transcatheter Heart Valve Replacement Market Size in USD million (2021-2030)

8. Transcatheter Heart Valve Replacement Market Company and Product Profiles

• 8.1. Medtronic
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. Boston Scientific Corporation
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. Bracco SpA
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. Edward Lifesciences
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. Meril Lifesciences
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. JenaValve Technologies Inc.
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. Venus Medtech (Hangzhou) Inc.
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. Abbott
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. Bluesail Medical Co., Ltd.
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy
• 8.10. Braile Biomedica
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy
• 8.11. CryoLife, Inc.
  • 8.11.1. Company Overview
  • 8.11.2. Company Snapshot
  • 8.11.3. Financial Overview
  • 8.11.4. Product Listing
  • 8.11.5. Entropy
• 8.12. SMT
  • 8.12.1. Company Overview
  • 8.12.2. Company Snapshot
  • 8.12.3. Financial Overview
  • 8.12.4. Product Listing
  • 8.12.5. Entropy
• 8.13. Peijia Medical Limited
  • 8.13.1. Company Overview
  • 8.13.2. Company Snapshot
  • 8.13.3. Financial Overview
  • 8.13.4. Product Listing
  • 8.13.5. Entropy
• 8.14. P+F Products + Features GmbH
  • 8.14.1. Company Overview
  • 8.14.2. Company Snapshot
  • 8.14.3. Financial Overview
  • 8.14.4. Product Listing
  • 8.14.5. Entropy
• 8.15. Livanova Plc
  • 8.15.1. Company Overview
  • 8.15.2. Company Snapshot
  • 8.15.3. Financial Overview
  • 8.15.4. Product Listing
  • 8.15.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us